351 related articles for article (PubMed ID: 22689860)
1. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
[TBL] [Abstract][Full Text] [Related]
2. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
3. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
[TBL] [Abstract][Full Text] [Related]
4. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Sivina M; Kreitman RJ; Arons E; Ravandi F; Burger JA
Br J Haematol; 2014 Jul; 166(2):177-88. PubMed ID: 24697238
[TBL] [Abstract][Full Text] [Related]
5. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS
Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207
[TBL] [Abstract][Full Text] [Related]
6. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
[TBL] [Abstract][Full Text] [Related]
7. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
8. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
[TBL] [Abstract][Full Text] [Related]
9. BTK inhibition in myeloma: targeting the seed and the soil.
Edwards CM
Blood; 2012 Aug; 120(9):1757-9. PubMed ID: 22936735
[No Abstract] [Full Text] [Related]
10. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
11. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
Chang BY; Huang MM; Francesco M; Chen J; Sokolove J; Magadala P; Robinson WH; Buggy JJ
Arthritis Res Ther; 2011 Jul; 13(4):R115. PubMed ID: 21752263
[TBL] [Abstract][Full Text] [Related]
12. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
Yang Y; Shi J; Gu Z; Salama ME; Das S; Wendlandt E; Xu H; Huang J; Tao Y; Hao M; Franqui R; Levasseur D; Janz S; Tricot G; Zhan F
Cancer Res; 2015 Feb; 75(3):594-604. PubMed ID: 25589346
[TBL] [Abstract][Full Text] [Related]
13. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase: oncotarget in myeloma.
Tai YT; Anderson KC
Oncotarget; 2012 Sep; 3(9):913-4. PubMed ID: 22989914
[TBL] [Abstract][Full Text] [Related]
15. Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.
Zheleznyak A; Mixdorf M; Marsala L; Prior J; Yang X; Cui G; Xu B; Fletcher S; Fontana F; Lanza G; Achilefu S
Theranostics; 2021; 11(16):7735-7754. PubMed ID: 34335961
[No Abstract] [Full Text] [Related]
16. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
[TBL] [Abstract][Full Text] [Related]
17. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss.
Shinohara M; Chang BY; Buggy JJ; Nagai Y; Kodama T; Asahara H; Takayanagi H
Bone; 2014 Mar; 60():8-15. PubMed ID: 24316417
[TBL] [Abstract][Full Text] [Related]
18. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
20. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
